Boston Scientific (XSWX:BSX) YoY EBITDA Growth: 10.08% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BSX Boston Scientific Corp XSWX:BSX
77 GF Score
Price CHF38.44
GF Value CHF86.18
! 1 Warning Sign
View Full Analysis

What is Boston Scientific YoY EBITDA Growth?

Boston Scientific XSWX:BSX 77 YoY EBITDA Growth is 10.08% as of Jun. 2026. GuruFocus rates XSWX:BSX with a GF Score™ of 77/100 and a GF Value™ of CHF86.18. The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Boston Scientific's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 10.08%.

Boston Scientific's EBITDA per Share for the three months ended in Jun. 2026 was CHF0.82.

Boston Scientific YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Boston Scientific's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boston Scientific YoY EBITDA Growth Chart

Boston Scientific Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 82.97 10.30 14.51 13.65 17.55

Boston Scientific Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.77 21.33 1.49 17.71 10.08
XSWX:BSX
77GF Score
Boston Scientific Corp XSWX:BSX
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Boston Scientific YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Boston Scientific's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(2.72-2.314)/ | 2.314 |
=17.55 %

Boston Scientific's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(0.819-0.744)/ | 0.744 |
=10.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 10.08% mean?
Boston Scientific (XSWX:BSX) has a YoY EBITDA Growth of 10.08% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Boston Scientific and its competitors.
Is Boston Scientific's YoY EBITDA Growth too high?
Boston Scientific's current YoY EBITDA Growth is 10.08%. Overall, Boston Scientific has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's YoY EBITDA Growth compare to EW and DXCM?
Boston Scientific's YoY EBITDA Growth of 10.08% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Boston Scientific and its competitors. Boston Scientific's current YoY EBITDA Growth is 10.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Boston Scientific (XSWX:BSX) has a current YoY EBITDA Growth of 10.08%. The stock's GF Value™ is CHF86.18, compared to a current price of CHF38.44 — trading 55.4% below its estimated fair value. The current YoY EBITDA Growth is 10.08%. Boston Scientific's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Boston Scientific (XSWX:BSX), the current YoY EBITDA Growth is 10.08% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Boston Scientific (XSWX:BSX) Overvalued in 2026?

Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued. The current stock price of CHF38.44 is trading 55.4% below its estimated GF Value™ of CHF86.18.

Key valuation signals for XSWX:BSX:

  • YoY EBITDA Growth: 10.08%
  • GF Value™: CHF86.18 vs. price of CHF38.44 (55.4% below fair value)
  • GF Score™: 77/100 with 1 warning sign

No single metric tells the full story. See the XSWX:BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Boston Scientific Business Description

Address 300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
77GF Score

Get the complete analysis for XSWX:BSX

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF38.44
Price
CHF86.18
GF Value